Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.28)
# 429
Out of 5,182 analysts
120
Total ratings
57.27%
Success rate
14.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Neutral | n/a | $39.47 | - | 9 | Apr 2, 2026 | |
| SLDB Solid Biosciences | Initiates: Buy | $26 | $7.45 | +248.99% | 1 | Mar 20, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $46 → $58 | $25.99 | +123.16% | 4 | Mar 4, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $224 → $284 | $273.44 | +3.86% | 5 | Feb 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $106 → $86 | $53.76 | +59.97% | 5 | Feb 25, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $41 → $45 | $28.82 | +56.14% | 2 | Feb 19, 2026 | |
| PEPG PepGen | Maintains: Buy | $6 → $7 | $1.60 | +337.50% | 3 | Feb 18, 2026 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $20 | $13.02 | +53.67% | 1 | Feb 11, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $64 → $52 | $24.92 | +108.67% | 4 | Jan 5, 2026 | |
| RZLT Rezolute | Maintains: Buy | $15 → $6 | $3.17 | +89.27% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $39 | $28.95 | +34.72% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $19 | $21.26 | -10.63% | 7 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $5.84 | +414.14% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $95 | $18.00 | +427.78% | 7 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $92 | $71.97 | +27.83% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $52.78 | +100.83% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $5.76 | +73.61% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $13.76 | +1.74% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $430.58 | +26.81% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $18.42 | +171.44% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $29.56 | +86.06% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.68 | +389.13% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $12.39 | +37.21% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.49 | +3.52% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $50.77 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $7.03 | +170.27% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.82 | +476.67% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.25 | +1,188.89% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $307.47 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $6.54 | +328.13% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.24 | +176.24% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $28.46 | +332.19% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $28.41 | +90.07% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.48 | +3,967.80% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.01 | - | 3 | Jun 26, 2017 |
Centessa Pharmaceuticals
Apr 2, 2026
Downgrades: Neutral
Price Target: n/a
Current: $39.47
Upside: -
Solid Biosciences
Mar 20, 2026
Initiates: Buy
Price Target: $26
Current: $7.45
Upside: +248.99%
Maze Therapeutics
Mar 4, 2026
Maintains: Buy
Price Target: $46 → $58
Current: $25.99
Upside: +123.16%
Krystal Biotech
Feb 25, 2026
Maintains: Buy
Price Target: $224 → $284
Current: $273.44
Upside: +3.86%
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Buy
Price Target: $106 → $86
Current: $53.76
Upside: +59.97%
NewAmsterdam Pharma Company
Feb 19, 2026
Maintains: Buy
Price Target: $41 → $45
Current: $28.82
Upside: +56.14%
PepGen
Feb 18, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $1.60
Upside: +337.50%
Entrada Therapeutics
Feb 11, 2026
Initiates: Buy
Price Target: $20
Current: $13.02
Upside: +53.67%
Ultragenyx Pharmaceutical
Jan 5, 2026
Maintains: Buy
Price Target: $64 → $52
Current: $24.92
Upside: +108.67%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $15 → $6
Current: $3.17
Upside: +89.27%
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $28.95
Upside: +34.72%
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $21.26
Upside: -10.63%
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $5.84
Upside: +414.14%
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $18.00
Upside: +427.78%
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $71.97
Upside: +27.83%
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $52.78
Upside: +100.83%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $5.76
Upside: +73.61%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $13.76
Upside: +1.74%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $430.58
Upside: +26.81%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $18.42
Upside: +171.44%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $29.56
Upside: +86.06%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.68
Upside: +389.13%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $12.39
Upside: +37.21%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.49
Upside: +3.52%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $50.77
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $7.03
Upside: +170.27%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.82
Upside: +476.67%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.25
Upside: +1,188.89%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $307.47
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $6.54
Upside: +328.13%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $7.24
Upside: +176.24%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $28.46
Upside: +332.19%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $28.41
Upside: +90.07%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.48
Upside: +3,967.80%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $25.01
Upside: -